COVID-19 Convalescent Plasma

Publication Date: August 16, 2022
Last Updated: August 16, 2022

Summary of Recommendations

The AABB suggests CCP transfusion in addition to the usual standard of care for outpatients with COVID-19 who are at high risk for disease progression. (C, M)
620
The AABB recommends against CCP transfusion for unselected hospitalized persons with moderate or severe disease. (S, H)
This recommendation does not apply to immunosuppressed patients or those who lack antibodies against SARS-CoV-2.
620
The AABB suggests CCP transfusion in addition to the usual standard of care for hospitalized patients with COVID-19 who do not have SARS-CoV-2 antibodies detected at admission. (C, L)
620
The AABB suggests CCP transfusion in addition to the usual standard of care for hospitalized patients with COVID-19 and preexisting immunosuppression. (C, L)
620
The AABB suggests against prophylactic CCP transfusion for uninfected persons with close contact exposure to a person with COVID-19. (C, L)
620

CCP is most effective when transfused with high neutralizing titers to infected patients early after symptom onset.

(U, U)
620

Recommendation Grading

Overview

Title

COVID-19 Convalescent Plasma

Authoring Organization

Publication Month/Year

August 16, 2022

Last Updated Month/Year

February 13, 2024

Supplemental Implementation Tools

Document Type

Guideline

Country of Publication

US

Document Objectives

Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a potential treatment of COVID-19. However, meta-analysis data and recommendations are limited. The Association for the Advancement of Blood and Biotherapies (AABB) developed clinical practice guidelines for the appropriate use of CCP.

Target Provider Population

Clinicians who are treating persons infected with SARS-CoV-2 and who are candidates for CCP transfusion

Inclusion Criteria

Male, Female, Adult, Older adult

Health Care Settings

Hospital, Laboratory services, Outpatient

Intended Users

Nurse, nurse practitioner, physician, physician assistant

Scope

Management

Diseases/Conditions (MeSH)

D017934 - Coronavirus, D010949 - Plasma

Keywords

Coronavirus, covid-19, COVID, Convalescent Plasma, CCP

Source Citation

Lise J. Estcourt, Claudia S. Cohn, Monica B. Pagano, et al; Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. Ann Intern Med. [Epub 16 August 2022]. doi:10.7326/M22-1079

Supplemental Methodology Resources

Data Supplement

Methodology

Number of Source Documents
139
Literature Search Start Date
January 1, 2019
Literature Search End Date
January 26, 2022